These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 31171572

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Soluble Urokinase Receptor and Chronic Kidney Disease.
    Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J.
    N Engl J Med; 2015 Nov 12; 373(20):1916-25. PubMed ID: 26539835
    [Abstract] [Full Text] [Related]

  • 3. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
    Weidemann DK, Abraham AG, Roem JL, Furth SL, Warady BA.
    Am J Kidney Dis; 2020 Aug 12; 76(2):194-202. PubMed ID: 31987488
    [Abstract] [Full Text] [Related]

  • 4. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M.
    Clin J Am Soc Nephrol; 2017 Sep 07; 12(9):1461-1469. PubMed ID: 28705885
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V, Theilade S, Winther SA, Tofte N, Eugen-Olsen J, Persson F, Hansen TW, Jeppesen J, Rossing P.
    Diabetes Care; 2019 Jun 07; 42(6):1112-1119. PubMed ID: 30885954
    [Abstract] [Full Text] [Related]

  • 7. Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.
    Schaefer F, Trachtman H, Wühl E, Kirchner M, Hayek SS, Anarat A, Duzova A, Mir S, Paripovic D, Yilmaz A, Lugani F, Arbeiter K, Litwin M, Oh J, Matteucci MC, Gellermann J, Wygoda S, Jankauskiene A, Klaus G, Dusek J, Testa S, Zurowska A, Caldas Afonso A, Tracy M, Wei C, Sever S, Smoyer W, Reiser J, ESCAPE Trial Consortium and the 4C Study Group.
    JAMA Pediatr; 2017 Nov 06; 171(11):e172914. PubMed ID: 28873129
    [Abstract] [Full Text] [Related]

  • 8. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.
    Raptis V, Loutradis C, Boutou AK, Faitatzidou D, Sioulis A, Ferro CJ, Papagianni A, Sarafidis PA.
    Cardiorenal Med; 2020 Nov 06; 10(6):440-451. PubMed ID: 33202410
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
    Jhee JH, Nam BY, Lee CJ, Park JT, Han SH, Kang SW, Park S, Yoo TH.
    J Am Heart Assoc; 2021 Jan 05; 10(1):e017225. PubMed ID: 33325248
    [Abstract] [Full Text] [Related]

  • 11. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC, Kim J, Cho A, Kim DH, Lee YK, Ryu H, Kim H, Oh KH, Oh YK, Hwang YH, Lee KB, Kim SW, Kim YH, Lee J, Ahn C, KNOW-CKD Investigators Group.
    J Korean Med Sci; 2020 Jun 08; 35(22):e165. PubMed ID: 32508065
    [Abstract] [Full Text] [Related]

  • 12. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
    Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
    Kidney Int; 2018 Mar 08; 93(3):691-699. PubMed ID: 29290310
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
    Hayek SS, Ko YA, Awad M, Ahmed H, Gray B, Hosny KM, Aida H, Tracy MJ, Wei C, Sever S, Reiser J, Quyyumi AA.
    Kidney Int Rep; 2017 May 08; 2(3):425-432. PubMed ID: 29142970
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B.
    Am J Nephrol; 2016 May 08; 44(3):171-8. PubMed ID: 27548646
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
    Heida JE, Gansevoort RT, Messchendorp AL, Meijer E, Casteleijn NF, Boertien WE, Zittema D, DIPAK Consortium.
    Clin J Am Soc Nephrol; 2021 Feb 08; 16(2):204-212. PubMed ID: 33504546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.